Jpmorgan Chase & CO Xilio Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,744 shares of XLO stock, worth $2,469. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,744
Previous 2,857
3.96%
Holding current value
$2,469
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding XLO
# of Institutions
32Shares Held
10MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA2.81MShares$2.52 Million0.46% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.3 Million19.12% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.44MShares$1.3 Million0.04% of portfolio
-
Atlas Venture Life Science Advisors, LLC993KShares$893,6200.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$812,2770.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $24.7M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...